Rhinomed (RNO) Stock Price, News & Analysis

Company Overview

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. The company offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. Its products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab. The company also engages in developing programs in various markets, including sleep and sleep architecture, the impact of sleep and respiratory, function on cognitive issues, obstructive sleep apnea, pain, nausea, respiratory disease, and diagnostics and sensors; and offers a drug delivery platform for the delivery of cannabinoid formulations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Cremorne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 452,773 shs
• Average Volume: N/A
• Market Capitalization: $11.47 million
• P/E Ratio: N/A
• Dividend Yield: 3.01%
• Price Target: N/A
• Consensus Rating: N/A

RNO Stock Analysis - Frequently Asked Questions

How were Rhinomed's earnings last quarter?

Rhinomed Limited (ASX:RNO) announced its quarterly earnings results on Thursday, February, 28th. The company reported ($0.02) earnings per share (EPS) for the quarter. Rhinomed had a negative net margin of 145.98% and a positive trailing twelve-month return on equity of 1,591.14%.

What other stocks do shareholders of Rhinomed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rhinomed investors own include Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Advanced Micro Devices (AMD), Lowe's Companies (LOW), Energy Vault (NRGV) and Medicine Man Technologies (SHWZ).

Company Calendar

• Last Earnings: 2/28/2019
• Today: 5/08/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: ASX:RNO
• CIK: N/A
• Web: www.rhinomed.com.au
• Phone: +61-3-84160900
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-10,910,000.00
• Net Margins: -145.98%
• Pretax Margin: N/A
• Return on Equity: 1,591.14%
• Return on Assets: -101.64%

Debt

• Debt-to-Equity Ratio: -93.28
• Current Ratio: 0.27
• Quick Ratio: 1.28

Sales & Book Value

• Annual Sales: $8.05 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 3.48
• Book Value: A($0.02) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 286,780,000
• Free Float: N/A
• Market Cap: $11.47 million
• Optionable: Not Optionable
• Beta: 0.88